Review Article
Curcumin and liver disease
Laura Vera-Ramirez,
Patricia Pérez-Lopez,
Alfonso Varela-Lopez,
MCarmen Ramirez-Tortosa,
Maurizio Battino,
José L. Quiles,
Laura Vera-Ramirez
GENyO Center Pfizer-University of Granada & Andalusian Government Centre for Genomics & Oncology, Granada, Spain
Department of Oncology, Complejo Hospitalario de Jaen, Jaen, Spain
Search for more papers by this authorPatricia Pérez-Lopez
Institute of Nutrition and Food Technology “José Mataix Verdú”, Department of Physiology, University of Granada, Granada, Spain
Search for more papers by this authorAlfonso Varela-Lopez
Institute of Nutrition and Food Technology “José Mataix Verdú”, Department of Physiology, University of Granada, Granada, Spain
Search for more papers by this authorMCarmen Ramirez-Tortosa
Institute of Nutrition and Food Technology “José Mataix Verdú”, Department of Biochemistry and Molecular Biology II, University of Granada, Granada, Spain
Search for more papers by this authorMaurizio Battino
Dipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche, Facoltà di Medicina, Università Politecnica delle Marche, Ancona, Italy
Search for more papers by this authorCorresponding Author
José L. Quiles
Institute of Nutrition and Food Technology “José Mataix Verdú”, Department of Physiology, University of Granada, Granada, Spain
Tel.:+34 958241000, Ext. 20316; Fax:+34 958241000 Ext. 20316
Instituto de Nutrición y Tecnología de los Alimentos “José Mataix Verdú”, Universidad de Granada, Centro de Investigación Biomédica, Parque Tecnológico de Ciencias de la Salud, Lab. 120, Avenida del Conocimiento s/n, 18071 Granada, SpainSearch for more papers by this author
Laura Vera-Ramirez,
Patricia Pérez-Lopez,
Alfonso Varela-Lopez,
MCarmen Ramirez-Tortosa,
Maurizio Battino,
José L. Quiles,
Laura Vera-Ramirez
GENyO Center Pfizer-University of Granada & Andalusian Government Centre for Genomics & Oncology, Granada, Spain
Department of Oncology, Complejo Hospitalario de Jaen, Jaen, Spain
Search for more papers by this authorPatricia Pérez-Lopez
Institute of Nutrition and Food Technology “José Mataix Verdú”, Department of Physiology, University of Granada, Granada, Spain
Search for more papers by this authorAlfonso Varela-Lopez
Institute of Nutrition and Food Technology “José Mataix Verdú”, Department of Physiology, University of Granada, Granada, Spain
Search for more papers by this authorMCarmen Ramirez-Tortosa
Institute of Nutrition and Food Technology “José Mataix Verdú”, Department of Biochemistry and Molecular Biology II, University of Granada, Granada, Spain
Search for more papers by this authorMaurizio Battino
Dipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche, Facoltà di Medicina, Università Politecnica delle Marche, Ancona, Italy
Search for more papers by this authorCorresponding Author
José L. Quiles
Institute of Nutrition and Food Technology “José Mataix Verdú”, Department of Physiology, University of Granada, Granada, Spain
Tel.:+34 958241000, Ext. 20316; Fax:+34 958241000 Ext. 20316
Instituto de Nutrición y Tecnología de los Alimentos “José Mataix Verdú”, Universidad de Granada, Centro de Investigación Biomédica, Parque Tecnológico de Ciencias de la Salud, Lab. 120, Avenida del Conocimiento s/n, 18071 Granada, SpainSearch for more papers by this authorAbstract
Liver diseases pose a major medical problem worldwide and a wide variety of herbs have been studied for the management of liver-related diseases. In this respect, curcumin has long been used in traditional medicine, and in recent years it has been the object of increasing research interest. In combating liver diseases, it seems clear that curcumin exerts a hypolipidic effect, which prevents the fatty acid accumulation in the hepatocytes that may result from metabolic imbalances, and which may cause nonalcoholic steatohepatitis. Another crucial protective activity of curcumin, not only in the context of chronic liver diseases but also regarding carcinogenesis and other age-related processes, is its potent antioxidant activity, which affects multiple processes and signaling pathways. The effects of curcumin on NF-κβ are crucial to our understanding of the potent hepatoprotective role of this herb-derived micronutrient. Because curcumin is a micronutrient that is closely related to cellular redox balance, its properties and activity give rise to a series of molecular reactions that in every case and biological situation affect the mitochondria. © 2013 BioFactors, 39(1):88–100, 2013
References
- 1 Williams, R. ( 2006) Global challenges in liver disease. Hepatology 44, 521–526.
- 2 Blouin, A., Bolender, R. P., and Weibel, E. R. ( 1977) Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study. J. Cell. Biol. 72, 441–455.
- 3 Si-Tayeb, K., Lemaigre, F. P., and Duncan, S. A. ( 2010) Organogenesis and development of the liver. Dev. Cell 18, 175–189.
- 4 Friedman, S. L. ( 2008) Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88, 125–172.
- 5 Vosough, M., Moslem, M., Pournasr, B., and Baharvand, H. ( 2011) Cell-based therapeutics for liver disorders. Br. Med. Bull. 100, 157–172.
- 6 Irshad, A., Anis, M., and Ackerman, S. J. ( 2012) Current role of ultrasound in chronic liver disease: surveillance, diagnosis and management of hepatic neoplasms. Curr. Probl. Diagn. Radiol. 41, 43–51.
- 7 Cauchy, F., Fuks, D., and Belghiti, J. ( 2012) HCC: current surgical treatment concepts. Langenbecks Arch. Surg. 397, 681–695.
- 8 El-Serag, H. B. ( 2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142, 1264–1273.
- 9 Spector, L. G. and Birch, J. ( 2012) The epidemiology of hepatoblastoma. Pediatr. Blood Cancer 59, 776–779.
- 10 Zimmermann, A. ( 2005) The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis. Eur. J. Cancer 41, 1503–1514.
- 11 Anderesen, J. B. and Thorgeirsson, S. S. ( 2012) Genetic profiling of intrahepatic cholangiocarcinoma. Curr. Opin. Gastroenterol. 28, 266–272.
- 12 Duan, X. F. and Li, Q. ( 2012) Primary hepatic angiosarcoma: a retrospective analysis of 6 cases. J. Dig. Dis. 13, 381–385.
- 13 Arias, I. M., Alter, H. J., Boyer, J. L., Cohen, D. E., Fausto, N., et al. ( 2009) The Liver Biology and Pathobiology, 5th edn. Wiley-Blackwell, West Sussex, UK.
- 14 Zhu, H., Jia, Z., Misra, H., and Li, Y. R. ( 2012) Oxidative stress and redox signaling mechanisms of alcoholic liver disease: updated experimental and clinical evidence. J. Dig. Dis. 13, 133–142.
- 15 Arduini, A., Serviddio, G., Tormos, A. M., Monsalve, M., and Sastre, J. ( 2012) Mitochondrial dysfunction in cholestatic liver diseases. Front. Biosci. (Elite Ed) 4, 2233–2252.
- 16 Longerich, T., Flechtenmacher, C., and Schirmacher, P. ( 2008) Quality and quantity in hepatopathology. Diagnostic and clinically relevant grading for non-tumourous liver diseases. Pathologe 29, 15–26.
- 17 Gieling, R. G., Burt, A. D., and Mann, D. A. ( 2008) Fibrosis and cirrhosis reversibility-molecular mechanisms. Clin. Liver Dis. 12, 915–937.
- 18 Rivera-Espinoza, Y. and Muriel, P. ( 2009) Pharmacological actions of curcumin in liver diseases or damage. Liver Int. 29, 1457–1466.
- 19 Nagarajan, P., Mahesh Kumar, M. J., Venkatesan, R., Majundar, S. S., and Juyal, R. C. ( 2012) Genetically modified mouse models for the study of nonalcoholic fatty liver disease. World J. Gastroenterol. 18, 1141–1153.
- 20 Siebler, J. and Galle, P. R. ( 2006) Treatment of nonalcoholic fatty liver disease. World J. Gastroenterol. 12, 2161–2167.
- 21 Ludwig, J., Viggiano, T. R., McGill, D. B., and Oh, B. J. ( 1980) Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55, 434–438.
- 22 Ramirez-Tortosa, M. C., Ramirez-Tortosa, C. L., Mesa, M. D., Granados, S., Gil, A., et al ( 2009) Curcumin ameliorates rabbit's steatohepatitis via respiratory chain, oxidative stress, and TNF-α. Free Radic. Biol. Med. 47, 924–931.
- 23 Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., and Bacon, B. R. ( 1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94, 2467–2474.
- 24 Day, C. P. and James, O. ( 1998) Steatohepatitis: a tale of two “hits”? Gastroenterology 114, 842–845.
- 25 Polyzos, S. A., Kountouras, J., Zavos, C., and Deretzi, G. ( 2012) Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J. Clin. Gastroenterol. 46, 272–284.
- 26 Yoshiyuki, U. ( 2012) The current endeavors to understand the pathogenesis of intractable liver diseases. Tohoku J. Exp. Med. 226, 171–175.
- 27 Hoofnagle, J. H. and di Bisceglie, A. M. ( 1997) The treatment of chronic viral hepatitis. N. Engl. J. Med. 336, 347–356.
- 28 Begriche, K., Massart, J., Robin, M. A., Borgne-Sanchez, A., and Fromenty, B. ( 2011) Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J. Hepatol. 54, 773–794.
- 29 Siddique, A. and Kowdley, K. V. ( 2012) Review article: the iron overload syndromes. Aliment. Pharmacol. Ther. 35, 876–893.
- 30 Abul, H., Mathew, T. C., Dashti, H. M., and Al-Bader, A. ( 2002) Level of superoxide dismutase, glutathione peroxidase and uric acid in thioacetamide-induced cirrhotic rats. Anat. Histol. Embryol. 31, 66–71.
- 31 ATSDR ( 2005). Toxicological profile for carbon tetrachloride (update), Agency for Toxic Substances and Disease Registry, Atlanta, p. 309.
- 32 Schuppan, D. and Afdhal, N. H. ( 2008) Liver cirrhosis. Lancet 371, 838–851.
- 33 Vinken, M. ( 2012) Gap junctions and non-neoplastic liver disease. J. Hepatol. 57, 655–662.
- 34 Funes, F. R., Silva, R. C., Arroyo, P. C. Jr., Duca, W. J., Silva, A. A., et al. ( 2012) Mortality and complications in patients with portal hypertension who underwent transjugular intrahepatic portosystemic shunt (TIPS)—12 years experience. Arq. Gastroenterol. 49, 143–149.
- 35 Kershenobich Stalnikowitz, D. and Weissbrod, A. B ( 2003) Liver fibrosis and inflammation. A review. Ann. Hepatol. 2, 159–163.
- 36 Vera-Ramirez, L., Sanchez-Rovira, P., Ramirez-Tortosa, M. C., Ramirez-Tortosa, C. L., Granados-Principal, S., et al. ( 2011) Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies. Crit. Rev. Oncol. Hematol. 80, 347–368.
- 37 Novo, E. and Parola, M. ( 2008) Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair 13, 5.
- 38 Holt, A. P., Salmon, M., Buckley, C. D., and Adams, D. H. ( 2008) Immune interactions in hepatic fibrosis. Clin. Liver Dis. 12, 861–882.
- 39 Consolo, M., Amoroso, A., Spandidos, D. A., and Mazzarino, M. C. ( 2009) Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease. Int. J. Mol. Med. 24, 143–152.
- 40 Paternostro, C., David, E., Novo, E., and Parola, M. ( 2010) Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J. Gastroenterol. 16, 281–288.
- 41 Parsons, M. J. and Green, D. R. ( 2011) Death receptors and mitochondria, life depends on the liver. Hepatology 54, 13–15.
- 42 Paik, Y. H., Iwaisako, K., Seki, E., Inokuchi, S., Schnabl, B., et al. ( 2011) The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. Hepatology 53, 173017–173041.
- 43 De Minicis, S. and Brenner, D. A. ( 2007) NOX in liver fibrosis. Arch. Biochem. Biophys. 462, 266–272.
- 44 Friedman, S. L. ( 2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655–1669.
- 45 Van Lint, J., Rykx, A., Maeda, Y., Vantus, T., Sturany, S., et al. ( 2002) Protein kinase D, an intracellular traffic regulator on the move. Trends Cell Biol. 12, 193–200.
- 46 Di Sario, A., Bendia, E., Svegliati-Baroni, G., Marzioni, M., Ridolfi, F., et al. ( 2002) Rearrangement of the cytoskeletal network induced by platelet-derived growth factor in rat hepatic stellate cells, role of different intracellular signalling pathways. J. Hepatol. 36, 179–190.
- 47 Bonacchi, A., Romagnani, P., Romanelli, R. G., Efsen, E., Annunziato, F., et al. ( 2001) Signal transduction by the chemokine receptor CXCR3, activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J. Biol. Chem. 276, 9945–9954.
- 48 Heymann, F., Trautwein, C., and Tacke, F. ( 2009) Monocytes and macrophages as cellular targets in liver fibrosis. Inflamm. Allergy Drug Targets 8, 307–318.
- 49 Ramm, G. A., Shepherd, R. W., Hoskins, A. C., Greco, S. A., Ney, A. D., et al. ( 2009) Fibrogenesis in pediatric cholestatic liver disease, role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology 49, 533–544.
- 50 Seki, E., de Minicis, S., Inokuchi, S., Taura, K., Miyai, K., et al. ( 2009) CCR2 promotes hepatic fibrosis in mice. Hepatology 50, 185–197.
- 51 Roebuck, K. A., Carpenter, L. R., Lakshminarayanan, V., Page, S. M., Moy, J. N., et al. ( 1999) Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and NF-kappaB. J. Leukoc. Biol. 65, 291–298.
- 52 Dienes, H. P. and Drebber, U. ( 2010) Pathology of immune-mediated liver injury. Dig. Dis. 28, 57–62.
- 53 Elsharkawy, A. M. and Mann, D. A. ( 2007) Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46, 590–597.
- 54 Park, H. J. and Youn, H. S. Mercury induces the expression of cyclooxygenase-2 and inducible nitric oxide synthase. Toxicol. Ind. Health, in press. doi: 10.1177/0748233711427048.
- 55 Chiarpotto, E., Castello, L., Leonarduzzi, G., Biasi, F., and Poli, G. ( 2005) Role of 4-hydroxy-2,3-nonenal in the pathogenesis of fibrosis. Biofactors 24, 229–236.
- 56 Dianzani, M. U., Barrera, G., and Parola, M. ( 1999) 4-Hydroxy-2,3-nonenal as a signal for cell function and differentiation. Acta Biochim. Pol. 46, 61–75.
- 57 Fernandez, M., Semela, D., Bruix, J., Colle, I., Pinzani, M., et al. ( 2009) Angiogenesis in liver disease. J. Hepatol. 50, 604–620.
- 58 Chaisson, M. L., Brooling, J. T., Ladiges, W., Tsai, S., and Fausto, N. ( 2002) Hepatocyte specific inhibition of NF-kappaB leads to apoptosis after TNF treatment, but not after partial hepatectomy. J. Clin. Invest. 110, 193–202.
- 59 Yuan, L. and Kaplowitz, N. ( 2009) Glutathione in liver diseases and hepatotoxicity. Mol. Aspects Med. 30, 29–41.
- 60 Diogo, C. V., Grattagliano, I., Oliveira, P. J., Bonfrate, L., and Portincasa, P. ( 2011) Re-wiring the circuit, mitochondria as a pharmacological target in liver disease. Curr. Med. Chem. 18, 5448–5465.
- 61 Micheau, O. and Tschopp, J. ( 2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114, 181–190.
- 62 Vandenabeele, P., Declercq, W., Van Herreweghe, F., and Vanden Berghe, T. ( 2010) The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci. Signal. 3, 4.
- 63 Parsons, C. J., Takashima, M., and Rippe, R. A. ( 2007) Molecular mechanisms of hepatic fibrogenesis. J. Gastroenterol. Hepatol. 22, 79–84.
- 64 García-Trevijano, E. R., Iraburu, M. J., Fontana, L., Domínguez-Rosales, J. A., Auster, A., et al. ( 1999) Transforming growth factor beta1 induces the expression of alpha1(I) procollagen mRNA by a hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate cells. Hepatology 29, 960–970.
- 65 Gressner, O. A., Lahme, B., Demirci, I., Gressner, A. M., and Weiskirchen, R. ( 2007) Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J. Hepatol. 47, 699–710.
- 66 Paradis, V., Dargere, D., Bonvoust, F., Vidaud, M., Segarini, P., et al. ( 2002) Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab. Invest. 82, 767–774.
- 67 Iizuka, M., Murata, T., Hori, M., and Ozaki, H. ( 2011) Increased contractility of hepatic stellate cells in cirrhosis is mediated by enhanced Ca2+-dependent and Ca2+-sensitization pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 300, 1010–1021.
- 68 Rhee, S. G. ( 2006) Cell signaling. H2O2, a necessary evil for cell signaling. Science 12, 1882–1883.
- 69 Boivin, B., Zhang, S., Arbiser, J. L., Zhang, Z. Y., and Tonks, N. K. ( 2008) A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cells. Proc. Natl. Acad. Sci. USA 105, 9959–9964.
- 70 Leclercq, I. A., Farrell, G. C., Field, J., Bell, D. R., Gonzalez, F. J., et al. ( 2001) CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 105, 1067–1075.
- 71 Kathirvel, E., Morgan, K., French, S. W., and Morgan, T. R. ( 2009) Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 21, 973–983.
- 72 Chanséaume, E., Tardy, A. L., Salles, J., Giraudet, C., Rousset, P., et al. ( 2007) Chronological approach of diet-induced alterations in muscle mitochondrial functions in rats. Obesity (Silver Spring) 15, 50–59.
- 73 Laurent, D., Yerby, B., Deacon, R., and Gao, J. ( 2007) Diet-induced modulation of mitochondrial activity in rat muscle. Am. J. Physiol. Endocrinol. Metab. 293, 1169–1177.
- 74 Krauss, S., Zhang, C. Y., Scorrano, L., Dalgaard, L. T., St-Pierre, J., et al. ( 2003) Superoxide mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. J. Clin. Invest. 112, 1831–1842.
- 75 Couplan, E., del Mar Gonzalez-Barroso, M., Alves-Guerra, M. C., Ricquier, D., Goubern, M., et al. ( 2002) No evidence for a basal, retinoic, or superoxide induced uncoupling activity of the uncoupling protein 2 present in spleen or lung mitochondria. J. Biol. Chem. 277, 26268–26275.
- 76 Silva, J. P., Shabalina, I. G., Dufour, E., Petrovic, N., Backlund, E. C., et al. ( 2005) SOD2 overexpression, enhanced mitochondrial tolerance but absence of effect on UCP activity. EMBO J. 24, 4061–4070.
- 77 Schreurs, M., Kuipers, F., and van der Leij, F. R. ( 2010) Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome. Obes. Rev. 11, 380–388.
- 78 Memon, R. A., Tecott, L. H., Nonogaki, K., Beigneux, A., Moser, A. H., et al. ( 2000) Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity, troglitazone induces expression of PPAR-gamma responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 141, 4021–4031.
- 79 Gupta, S. C., Patchva, S., Koh, W., and Aggarwal, B. B. ( 2012) Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin. Exp. Pharmacol. Physiol. 39, 283–299.
- 80 Ghosh, N., Ghosh, R., Mandal, V., and Mandal, S. C. ( 2011) Recent advances in herbal medicine for treatment of liver diseases. Pharm. Biol. 49, 970–988.
- 81 Matsuda, H., Ninomiya, K., Morikawa, T., and Yoshikawa, M. ( 1998) Inhibitory effect and action mechanism of sesquiterpenes from Zedoariae Rhizoma on D-galactosamine/lipopolysaccharide-induced liver injury. Bioorg. Med. Chem. Lett. 17, 339–344.
- 82 Morikawa, T., Matsuda, H., Ninomiya, K., and Yoshikawa, M. ( 2002) Medicinal foodstuffs. XXIX. Potent protective effects of sesquiterpenes and curcumin from Zedoariae Rhizoma on liver injury induced by D-galactosamine/lipopolysaccharide or tumor necrosis factor-alpha. Biol. Pharm. Bull. 25, 627–631.
- 83 Lukita-Atmadja, W., Ito, Y., Baker, G. L., and McCuskey, R. S. ( 2002) Effect of curcuminoids as anti-inflammatory agents on the hepatic microvascular response to endotoxin. Shock 17, 399–403.
- 84 Kaur, G., Tirkey, N., Bharrhan, S., Chanana, V., Rishi, P., et al. ( 2006) Inhibition of oxidative stress and cytokine activity by curcumin in amelioration of endotoxin-induced experimental hepatoxicity in rodents. Clin. Exp. Immunol. 145, 313–321.
- 85 Yun, S. S., Kim, S. P., Kang, M. Y., and Nam, S. H. ( 2010) Inhibitory effect of curcumin on liver injury in a murine model of endotoxemic shock. Biotechnol. Lett. 32, 209–214.
- 86 Cerný, D., Lekić, N., Váňová, K., Muchová, L., Hořínek, A., et al. ( 2011) Hepatoprotective effect of curcumin in lipopolysaccharide/-galactosamine model of liver injury in rats: relationship to HO-1/CO antioxidant system. Fitoterapia 82, 786–791.
- 87 Kim, K. M., Pae, H. O., Zhung, M., Ha, H. Y., Ha, Y. A., et al. ( 2008) Involvement of anti-inflammatory heme oxygenase-1 in the inhibitory effect of curcumin on the expression of pro-inflammatory inducible nitric oxide synthase in RAW264.7 macrophages. Biomed. Pharmacother. 62, 630–636.
- 88 Liang, G., Li, X., Chen, L., Yang, S., Wu, X., et al. ( 2008) Synthesis and anti-inflammatory activities of mono-carbonyl analogues of curcumin. Bioorg. Med. Chem. Lett. 18, 1525–1529.
- 89 Weisberg, S. P., Leibel, R., and Tortoriello, D. V. ( 2008) Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 149, 3549–2558.
- 90 Samuhasaneeto, S., Thong-Ngam, D., Kulaputana, O., Suyasunanont, D., and Klaikeaw, N. ( 2009) Curcumin decreased oxidative stress, inhibited NF-kappaB activation, and improved liver pathology in ethanol-induced liver injury in rats. J. Biomed. Biotechnol. 2009, 981963.
- 91 Shapiro, H., Ashkenazi, M., Weizman, N., Shahmurov, M., Aeed, H., et al. ( 2006) Curcumin ameliorates acute thioacetamide-induced hepatotoxicity. J. Gastroenterol. Hepatol. 21, 358–366.
- 92 Bisht, S., Khan, M. A., Bekhit, M., Bai, H., Cornish, T., et al. ( 2011) A polymeric nanoparticle formulation of curcumin (NanoCurc™) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation. Lab. Invest. 91, 1383–1395.
- 93 Leclercq, I. A., Farrell, G. C., Sempoux, C., de la Peña, A., and Horsmans, Y. ( 2004) Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J. Hepatol. 41, 926–934.
- 94 Charoensuk, L., Pinlaor, P., Prakobwong, S., Hiraku, Y., Laothong, U., et al. ( 2011) Curcumin induces a nuclear factor-erythroid 2-related factor 2-driven response against oxidative and nitrative stress after praziquantel treatment in liver fluke-infected hamsters. Int. J. Parasitol. 41, 615–626.
- 95 Mouzaoui, S., Rahim, I., and Djerdjouri, B. ( 2012) Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-α-induced oxidative stress, colitis and hepatotoxicity in mice. Int. Immunopharmacol. 12, 302–311.
- 96 Nanji, A. A., Jokelainen, K., Tipoe, G. L., Rahemtulla, A., Thomas, P., et al. ( 2003) Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. Am. J. Physiol. Gastrointest. Liver Physiol. 284, 321–327.
- 97 Bassiouny, A. R., Zaky, A., and Kandeelm K. M. ( 2011) Alteration of AP-endonuclease1 expression in curcumin-treated fibrotic rats. Ann. Hepatol. 10, 516–530.
- 98 Reyes-Gordillo, K., Segovia, J., Shibayama, M., Tsutsumi, V., Vergara, P., et al. ( 2008) Curcumin prevents and reverses cirrhosis induced by bile duct obstruction or CCl4 in rats: role of TGF-beta modulation and oxidative stress. Fundam. Clin. Pharm. 22, 417–427.
- 99 Lin, Y. L., Lin, C. Y., Chi, C. W., and Huang, Y. T. ( 2009) Study on antifibrotic effects of curcumin in rat hepatic stellate cells. Phytother. Res. 23, 927–932.
- 100 Shu, J. C., He, Y. J., Lv, X., Ye, G. R., and Wang, L. X. ( 2009) Curcumin prevents liver fibrosis by inducing apoptosis and suppressing activation of hepatic stellate cells. J. Nat. Med. 63, 415–420.
- 101 Nakayama, N., Nakamura, T., Okada, H., Iwaki, S., Sobel, B. E., et al. ( 2011) Modulators of induction of plasminogen activator inhibitor type-1 in HepG2 cells by transforming growth factor-β. Coronary Artery Dis. 22, 468–478.
- 102 Tu, C. T., Han, B., Yao, Q. Y., Zhang, Y. A., Liu, H. C., et al. ( 2012) Curcumin attenuates Concanavalin A-induced liver injury in mice by inhibition of Toll-like receptor (TLR) 2, TLR4 and TLR9 expression. Int. Immunopharmacol. 12, 151–157.
- 103 Tu, C. T., Yao, Q. Y., Xu, B. L., Wang, J. Y., Zhou, C. H., et al. ( 2012) Protective effects of curcumin against hepatic fibrosis induced by carbon tetrachloride: modulation of high-mobility group box 1, Toll-like receptor 4 and 2 expression. Food Chem. Toxicol. 50, 3343–3351.
- 104 Park, E. J., Jeon, C. H., Ko, G., Kim, J., and Sohn, D. H. ( 2000) Protective effect of curcumin in rat liver injury induced by carbon tetrachloride. J. Pharm. Pharmacol. 52, 437–440.
- 105 Wu, S. J., Lin, Y. H., Chu, C. C., Tsai, Y. H., and Chao, J. C. ( 2008) Curcumin or saikosaponin a improves hepatic antioxidant capacity and protects against CCl4-induced liver injury in rats. J. Med. Food 11, 224–229.
- 106 Pari, L. and Murugan, P. ( 2004) Protective role of tetrahydrocurcumin against erythromycin estolate-induced hepatotoxicity. Pharmacol. Res. 49, 481–486.
- 107 Pari, L. and Amali, R. ( 2005) Protective role of tetrahydrocurcumin (THC) an active principle of turmeric on chloroquine induced hepatotoxicity in rats. J. Pharm. Pharm. Sci. 8, 115–123.
- 108 Naik, S. R., Thakare, V. N., and Patil, S. R. ( 2011) Protective effect of curcumin on experimentally induced inflammation, hepatotoxicity and cardiotoxicity in rats, evidence of its antioxidant property. Exp. Toxicol. Pathol. 63, 419–431.
- 109 Rong, S., Zhao, Y., Bao, W., Xiao, X., Wang, D., et al. ( 2012) Curcumin prevents chronic alcohol-induced liver disease involving decreasing ROS generation and enhancing antioxidative capacity. Phytomedicine 19, 545–550.
- 110 Eybl, V., Kotyzova, D., and Koutensky, J. ( 2006) Comparative study of natural antioxidants - curcumin, resveratrol and melatonin - in cadmium-induced oxidative damage in mice. Toxicology 225, 150–156.
- 111 Girish, C., Koner, B. C., Jayanthi, S., Ramachandra, R. K., Rajesh, B., et al. ( 2009) Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice. Fundam. Clin. Pharm. 23, 735–745.
- 112 Yousef, M. I., Omar, S. A., El-Guendi, M. I., and Abdelmegid, L. A. ( 2010) Potential protective effects of quercetin and curcumin on paracetamol-induced histological changes, oxidative stress, impaired liver and kidney functions and haematotoxicity in rat. Food Chem. Toxicol. 48, 3246–3261.
- 113 Rao, D. S., Sekhara, N. C., Satyanarayana, M. N., and Srinivasan, M. ( 1970) Effect of curcumin on serum and liver cholesterol levels in the rat. J. Nutr. 100, 1307–1315.
- 114 Asai, A. and Miyazawa, T. ( 2001) Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. J. Nutr. 131, 2932–2935.
- 115 Rukkumani, R., Sri Balasubashini, M., Vishwanathan, P., and Menon, V. P. ( 2002) Comparative effects of curcumin and photo-irradiated curcumin on alcohol- and polyunsaturated fatty acid-induced hyperlipidemia. Pharmacol. Res. 46, 257–264.
- 116 Rukkumani, R., Aruna, K., Varma, P. S., Viswanathan, P., Rajasekaran, K. N., et al. ( 2005) Protective role of a novel curcuminoid on alcohol and PUFA-Induced hyperlipidemia. Toxicol. Mech. Methods 15, 227–234.
- 117 Jang, E. M., Choi, M. S., Jung, U. J., Kim, M. J., Kim, H. J., et al ( 2008) Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism 57, 1576–1583.
- 118 Shao, W., Yu, Z., Chiang, Y., Yang, Y., Chai, T., et al. ( 2012) Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One 7, 28784.
- 119 Li, J. M., Li, Y. C., Kong, L. D., and Hu, Q. H. ( 2010) Curcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats. Hepatology 51, 1555–1566.
- 120 Kang, Q. and Chen, A. ( 2009) Curcumin eliminates oxidized LDL roles in activating hepatic stellate cells by suppressing gene expression of lectin-like oxidized LDL receptor-1. Lab. Invest. 89, 1275–1290.
- 121 Guangwei, X., Rongzhu, L., Wenrong, X., Suhua, W., Xiaowu, Z., et al. ( 2010) Curcumin pretreatment protects against acute acrylonitrile-induced oxidative damage in rats. Toxicology 267, 140–146.
- 122 Farombi, E. O., Shrotriya, S., Na, H. K., Kim, S. H., and Surh, Y. J. ( 2008) Curcumin attenuates dimethylnitrosamine-induced liver injury in rats through Nrf2-mediated induction of heme oxygenase-1. Food Chem. Toxicol. 46, 1279–1287.
- 123 Lin, J. and Chen, A. ( 2008) Activation of peroxisome proliferator-activated receptor-gamma by curcumin blocks the signaling pathways for PDGF and EGF in hepatic stellate cells. Lab. Invest. 88, 529–540.
- 124 Kuo, J. J., Chang, H. H., Tsai, T. H., and Lee, T. Y. ( 2012) Positive effect of curcumin on inflammation and mitochondrial dysfunction in obese mice with liver steatosis. Int. J. Mol. Med. 30, 673–679.
- 125 He, S. M., Chan, E., and Zhou, S. F. ( 2011) ADME properties of herbal medicines in humans: evidence, challenges and strategies. Curr. Pharm. Des. 17, 357–407.
- 126 Sharma, R. A., Steward, W. P., and Gescher, A. J. ( 2007) Pharmacokinetics and pharmacodynamics of curcumin. Adv. Exp. Med. Biol. 595, 453–470.
- 127 Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M., Ho, Y. F., et al. ( 2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21, 2895–2900.
- 128 Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., et al. ( 1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 64, 353–356.
- 129 Kanai, M., Imaizumi, A., Otsuka, Y., Sasaki, H., Hashiguchi, M., et al. ( 2012) Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother. Pharmacol. 69, 65–70.
- 130 Maiti, K., Mukherjee, K., Gantait, A., Saha, B. P., and Mukherjee, P. K. ( 2007) Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm. 330, 155–163.
- 131 Lao, C. D., Ruffin, M. T. IV, Normolle, D., Heath, D. D., Murray, S. I., et al. ( 2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern. Med. 6, 10.
- 132 Balaji, S. and Chempakam, B. ( 2010) Toxicity prediction of compounds from turmeric (Curcuma longa L). Food Chem. Toxicol. 48, 2951–2959.
- 133 Quiles, J. L., Huertas, J. R., Mañas, M., Ochoa, J. J., Battino, M., et al. ( 1999) Oxidative stress induced by exercise and dietary fat modulates the coenzyme Q and vitamin A balance between plasma and mitochondria. Int. J. Vitam. Nutr. Res. 69, 243–249.
- 134 Battino, M., Quiles, J. L., Huertas, J. R., Ramirez-Tortosa, M. C., Cassinello, M., et al. ( 2002) Feeding fried oil changes antioxidant and fatty acid pattern of rat and affects rat liver mitochondrial respiratory chain components. J. Bioenerg. Biomembr. 34, 127–134.
- 135 Quiles, J. L., Huertas, J. R., Battino, M., Ramírez-Tortosa, M. C., Cassinello, M., et al. ( 2002) The intake of fried virgin olive or sunflower oils differentially induces oxidative stress in rat liver microsomes. Br. J. Nutr. 88, 57–65.
- 136 Ochoa, J. J., Quiles, J. L., Ibáñez, S., Martínez, E., López-Frías, M., et al. ( 2003) Aging-related oxidative stress depends on dietary lipid source in rat postmitotic tissues. J. Bioenerg. Biomembr. 35, 267–275.
- 137 Mancuso, M., Orsucci, D., Filosto, M., Simoncini, C., and Siciliano, G. ( 2012) Drugs and mitochondrial diseases: 40 queries and answers. Expert Opin. Pharmacother. 13, 527–543.
Citing Literature
